DVAX · As filed with the SEC

Dynavax Technologies income statement, by quarter

The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands

USD thousands, except per-share amounts; shares in thousandsQ3 2025
3 months ended Sep 30, 2025
Q2 2025
3 months ended Jun 30, 2025
Q1 2025
3 months ended Mar 31, 2025
Q4 2024†
3 months ended Dec 31, 2024
Revenues:
Total revenues94,87695,44268,16472,032†
Product revenue, net89,95491,87264,95971,053†
Other revenue4,9223,5703,205979†
Operating expenses:
Cost of sales - product14,40314,03513,76913,410†
Research and development19,11616,61919,37718,669†
Selling, general and administrative40,08650,35947,67841,585†
Gain on sale of assets (Note 8)———0†
Bad debt expense (Note 9)———0†
Bad debt expense0010,970—
Total operating expenses73,60581,01391,79473,664†
Income (loss) from operations21,27114,429(23,630)(1,632)†
Other income (expense):
Interest income6,5936,7987,7398,414†
Interest expense(1,643)(1,641)(1,692)(1,704)†
Sublease income2,2252,2262,226—
Loss on debt extinguishment00(82,095)—
Other loss(27)(596)(423)345†
Net income (loss) before income taxes28,41921,216(97,875)7,629†
Provision for income taxes(1,492)(2,495)1,776(579)†
Net income (loss)26,92718,721(96,099)7,050†
Net income (loss) per share:
Basic (in USD per share)0.230.16(0.77)—
Diluted (in USD per share)0.210.14(0.77)—
Weighted-average shares used in computing net income (loss) per share:
Basic (in shares)117,307119,317124,871—
Diluted (in shares)136,468138,356124,871—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.